Literature DB >> 10888627

Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells.

I Dmitriev1, E Kashentseva, B E Rogers, V Krasnykh, D T Curiel.   

Abstract

Human adenovirus (Ad) is extensively used for a variety of gene therapy applications. However, the utility of Ad vectors is limited due to the low efficiency of Ad-mediated gene transfer to target cells expressing marginal levels of the Ad fiber receptor. Therefore, the present generation of Ad vectors could potentially be improved by modification of Ad tropism to target the virus to specific organs and tissues. The fact that coxsackievirus and adenovirus receptor (CAR) does not play any role in virus internalization, but functions merely as the virus attachment site, suggests that the extracellular part of CAR might be utilized to block the receptor recognition site on the Ad fiber knob domain. We proposed to design bispecific fusion proteins formed by a recombinant soluble form of truncated CAR (sCAR) and a targeting ligand. In this study, we derived sCAR genetically fused with human epidermal growth factor (EGF) and investigated its ability to target Ad infection to the EGF receptor (EGFR) overexpressed on cancer cell lines. We have demonstrated that sCAR-EGF protein is capable of binding to Ad virions and directing them to EGFR, thereby achieving targeted delivery of reporter gene. These results show that sCAR-EGF protein possesses the ability to effectively retarget Ad via a non-CAR pathway, with enhancement of gene transfer efficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888627      PMCID: PMC112205          DOI: 10.1128/jvi.74.15.6875-6884.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types.

Authors:  T J Wickham; P W Roelvink; D E Brough; I Kovesdi
Journal:  Nat Biotechnol       Date:  1996-11       Impact factor: 54.908

2.  Targeted gene delivery by tropism-modified adenoviral vectors.

Authors:  J T Douglas; B E Rogers; M E Rosenfeld; S I Michael; M Feng; D T Curiel
Journal:  Nat Biotechnol       Date:  1996-11       Impact factor: 54.908

3.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Targeted adenovirus-mediated gene delivery to T cells via CD3.

Authors:  T J Wickham; G M Lee; J A Titus; G Sconocchia; T Bakács; I Kovesdi; D M Segal
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.

Authors:  P W Roelvink; A Lizonova; J G Lee; Y Li; J M Bergelson; R W Finberg; D E Brough; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Use of a novel cross-linking method to modify adenovirus tropism.

Authors:  B E Rogers; J T Douglas; C Ahlem; D J Buchsbaum; J Frincke; D T Curiel
Journal:  Gene Ther       Date:  1997-12       Impact factor: 5.250

7.  The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery.

Authors:  S J Watkins; V V Mesyanzhinov; L P Kurochkina; R E Hawkins
Journal:  Gene Ther       Date:  1997-10       Impact factor: 5.250

8.  The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses.

Authors:  J M Bergelson; A Krithivas; L Celi; G Droguett; M S Horwitz; T Wickham; R L Crowell; R W Finberg
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Adenoviral-mediated gene transfer in lymphocytes.

Authors:  R P Leon; T Hedlund; S J Meech; S Li; J Schaack; S P Hunger; R C Duke; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.

Authors:  I Dmitriev; V Krasnykh; C R Miller; M Wang; E Kashentseva; G Mikheeva; N Belousova; D T Curiel
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  50 in total

1.  Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines.

Authors:  Toshiro Seki; Igor Dmitriev; Elena Kashentseva; Koichi Takayama; Marianne Rots; Kaori Suzuki; David T Curiel
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.

Authors:  Hyunjung Baek; Hiroaki Uchida; Kyungok Jun; Jae-Hong Kim; Masahide Kuroki; Justus B Cohen; Joseph C Glorioso; Heechung Kwon
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

3.  Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.

Authors:  Nikolay Korokhov; Galina Mikheeva; Alexander Krendelshchikov; Natalya Belousova; Vera Simonenko; Valentina Krendelshchikova; Alexander Pereboev; Alexander Kotov; Olga Kotova; Pierre L Triozzi; Wayne A Aldrich; Joanne T Douglas; Kin-Ming Lo; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 4.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

5.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

6.  Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation.

Authors:  A Pereboev; L Pereboeva; D T Curiel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 7.  Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.

Authors:  Sabine Boeckle; Ernst Wagner
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

Review 8.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

9.  Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter.

Authors:  M H Verheije; T Würdinger; V W van Beusechem; C A M de Haan; W R Gerritsen; P J M Rottier
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 10.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.